- Home Depot (HD) to buy from neutral at Goldman.
- Delta Air Lines (DAL) to buy from neutral at BofA/Merrill.
- Heico (HEI) to outperform from sector perform at RBC Capital.
- Royal Dutch Shell (RDS.A) to outperform from neutral at Credit Suisse.
- MB Financial (MBFI) to outperform from neutral at RW Baird.
- Quest Diagnostics (DGX) to equal weight from underweight at Morgan Stanley.
- Oshkosh (OSK) to neutral from underweight at JPMorgan.
- Volterra (VLTR) and Silicon Laboratories (SLAB) to buy from neutral at Roth Capital.
- Ascena Retail Group (ASNA) to overweight from neutral at Piper Jaffray.
- Cytec Industries (CYT) to buy from hold at Deutsche Bank.
rdea posts
FeedAnalyst Calls: DAL, CIEN, DGX, HD, IMAX, LOW, OSK, PENN, RDS.A, SWK ...
Continue reading Analyst Calls: DAL, CIEN, DGX, HD, IMAX, LOW, OSK, PENN, RDS.A, SWK ...
Analyst Upgrades, Downgrades and Initiations: ACN, ADBE, BBY, DIS, FSLR, GILD, ZNT ...
- FBR Capital upgraded Adobe Systems (ADBE) to outperform from market perform to reflect valuation following the recent pullback in shares, as well as the upcoming release of the company's CS5 product. The firm raised its price target for the stock to $39 from $36.
- Keefe Bruyette upgraded Zenith National (ZNT) to market perform from underperform following the company's merger agreement with Fairfax Financial. The firm thinks the offer is a strong price to receive for Zenith National shareholders.
- Kaufman Bros. upgraded Infosys (INFY) to buy from hold as it believes the offshore applications outsourcing market is picking up. The firm raised its target price for shares to $67 from $58.
- Ventas (VTR) was upgraded to buy from neutral at BofA/Merrill.
- Liz Claiborne (LIZ) was upgraded to buy from hold at KeyBanc.
- iStar Financial (SFI) was upgraded to hold from sell at Citigroup.
Analyst Upgrades, Downgrades and Initiations: APA, BKC, CAT, NFLX, KFT, QCOM, ROK ...
- Jefferies upgraded Netflix (NFLX) to buy from hold and has a $65 target, citing stronger than expected momentum following the Q4 report and guidance. Merriman upgraded Netflix to buy from neutral following the company's better-than-expected Q4 results as it sees upside in shares to the $66 to $75 range. Shares were also upgraded to buy from underperform at BofA/Merrill.
- Citigroup upgraded Rockwell Automation (ROK) to hold from sell following the company's better-than-expected Q1 results and raised FY10 guidance. Citi raised its target on shares to $52 from $35.
- Deutsche Bank upgraded Textainer (TGH) to buy from hold to reflect improved container fundamentals and potential fleet growth. The firm keeps a $19 price target on shares.
- STMicroelectronics (STM) was upgraded to neutral from underweight at Piper Jaffray.
- Caterpillar (CAT) was upgraded to neutral from sell at UBS.
- Apache (APA) was upgraded to outperform from market perform at Wells Fargo.
Analyst upgrades, downgrades and initiations: JCG, K, MON, TOL, TXN ...
- Toll Brothers (NYSE: TOL) was upgraded to Buy at Citigroup. The firm views the recent sell-off in home building stocks as a buying opportunity and thinks Toll Brothers offers the best risk/reward in its coverage universe. Citi keeps a $23 price target on the stock.
- Kellogg (NYSE: K) was upgraded to Buy from Hold at Citigroup following the Q3 results, as it believes the company's reduced spending and share buyback will serve as catalysts. The firm raised its price target on shares to $63 from $50.
- Rogers Communications (NYSE: RCI) and Telus (NYSE: TU) were upgraded to Outperform from Sector Perform at RBC Capital, which said the CRTC unexpectedly denied Globalive's wireless application. The analyst said Globalive was potentially the biggest of new wireless competitors and the decision removes a big threat to the group. Rogers price target was raised to $40 from $33; Telus to $44 from $36.
- Stanley (NYSE: SXE) was upgraded at Wells Fargo to Outperform from Market Perform after the company reported better-than-expected Q3 results and raised its FY10 guidance.
- Texas Instruments (NYSE: TXN) was upgraded at Bernstein to Outperform from Market Perform. The analyst believes Texas Instruments' core business earnings power is underappreciated and valuation is attractive. Target raised to $30 from $28.
Continue reading Analyst upgrades, downgrades and initiations: JCG, K, MON, TOL, TXN ...
Analyst upgrades, downgrades and initiations: AKS, LEN, MAR, DE, KLAC, VIVEF ...
Analyst upgrades:- KeyBanc upgraded Epicor (NASDAQ: EPIC) to Buy from Hold based on several near-term catalysts that include possible convertible debt repurchases, reasonable Q4 results, a proxy fight, and a boost from the Epicor 9 product cycle in 2H09.
- KeyBanc also upgraded AK Steel (NYSE: AKS) to Buy from Hold based on relative valuation and said the company could benefit from lower iron ore, scrap natural gas, and labor inputs.
- JP Morgan upgraded Lennar (NYSE: LEN) to Overweight from Neutral based on relative valuation.
- Marriott (NYSE: MAR) was upgraded to Buy from Neutral at Goldman.
- Raymond James (NYSE: RJF) was raised to Market Perform from Underperform at Wachovia.
- Deere (NYSE: DE) was upgraded to Outperform from Market Perform at Bernstein.
Continue reading Analyst upgrades, downgrades and initiations: AKS, LEN, MAR, DE, KLAC, VIVEF ...
Analyst initiations: Syntroleum, Pervasive Software, Ardea Biosciences
MOST NOTEWORTHY: Syntroleum, Pervasive Software and Ardea Biosciences were today's noteworthy initiations:- Merrriman believes Syntroleum (NASDAQ: SYNM) possesses the technological platforms with its Biofining process and the cost structures with its Tyson Foods (NYSE: TSN) relationship needed to commercialize clean synthetic fuels. The firm started shares with a Buy rating.
- Pervasive Software (NASDAQ: PVSW) was assumed with a Buy rating and $7 target at B. Riley, as they find shares attractive in this market given the company's solid balance sheet with a sizeable cash balance and positive operating cash flow. They believe the stock is undervalued at current levels.
- Ardea Biosciences (NASDAQ: RDEA) was assumed with an Outperform rating at Cowen. The firm believes Ardea has a promising clinical pipeline for HIV, gout, and cancer.
Analyst initiations: EFII, FNDT and VIAP
MOST NOTEWORTHY: Electronics for Imaging, Fundtech and VIA Pharmaceuticals were today's noteworthy initiations:- Banc of America initiated Electronics for Imaging (NASDAQ: EFII) with a Buy rating and $26.50 target, as it sees leverage potential in 2008 from cost reductions and revenue mix and believes stronger controller revenue mix and ink from inkjets could help gross margin in 2H08.
- JMP Securities expects Fundtech (NASDAQ: FNDT) to benefit from an upgrade cycle among large banks to improve their payment systems, starting shares off with a Market Outperform rating and $19 target.
- Rodman & Renshaw resumed coverage of VIA Pharmaceuticals (NASDAQ: VIAP) with an Outperform rating and $4 target. The firm expects VIAP's VIA-2291, a treatment for Antherosclerosis, Ph II data expected in mid-2008 to drive shares.
- Oppenheimer initiated Ardea Biosciences (NASDAQ: RDEA) with a Buy rating and $15 target.
- SAP AG (NASDAQ: SAP) was initiated with an Equal Weight rating at Lehman.
- CIBC resumed coverage of Limelight Networks (NASDAQ: LLNW) with a Sector Outperformer rating.
Analyst initiations: CNQR, TSON and TWTI
MOST NOTEWORTHY: Concur Tech, TranS1 and Third Wave were today's noteworthy initiations:- Broadpoint initiated Concur Tech (NASDAQ: CNQR) with a Strong Buy rating and $40 target. The firm believes Concur has attractive growth drivers, room for leverage, and is a market leader for innovation and growth. Wachovia is positive on TraS1's AxiaLIF procedure in lumbar fusions as it is less invasive and patients have a faster recovery period. The firm views the potential market at over $1B and started shares off with an Outperform rating.
- Shares of TranS1 (NASDAQ: TSON) were also initiated with a Buy rating and $27 target at Piper Jaffray, as they believe the company's focus on minimally invasive surgical technique for treating lower back pain provides a large market opportunity, and at Cowen with an Outperform rating, as they positive on TSON's minimally invasive platform in spinal fusions that should leaded rapid growth.
- Collins Stewart said Third Wave (NASDAQ: TWTI) is on track to file PMA submissions for 2 new screening tests for HPV by early next year and started shares with a Buy rating and $11 target.
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Walmart's New Health Food Push: Is It Too Hard to Swallow?





